CONMED (US:CNMD)2024-07-31 22:30Financial Performance - Q2 2024 - Worldwide revenue reached $332.1 million, representing a 5.2% increase in constant currency[11] - General Surgery revenue grew by 9.4% in constant currency[12] - Orthopedic Surgery revenue decreased by 0.1%[12] - Single-use products saw a 6.2% revenue increase[12] - GAAP EPS was $0.96, a 123.3% increase year-over-year, while adjusted EPS was $0.98, an 18.1% increase[12] Financial Performance - June 2024 YTD - Worldwide revenue totaled $644.4 million, a 5.5% increase in constant currency[14, 15] - General Surgery revenue increased by 8.8% in constant currency[15] - Domestic revenue grew by 6.6%, while international revenue increased by 4.1%[15] - Single-use products revenue grew by 6.2%, and capital products revenue increased by 1.8%[15] - GAAP EPS was $1.59, a 224.5% increase year-over-year, while adjusted EPS was $1.78, a 19.5% increase[15] Market Opportunities - Orthopedics market represents a large opportunity, with one market share point worth ~$52 million in Sports Medicine & Biologics, ~$35 million in Capital Equipment, and ~$49 million in Foot & Ankle[9] - General Surgery market also presents significant potential, with one market share point valued at ~$16 million in Access, ~$32 million in Energy, ~$17 million in Instruments, ~$32 million in Endoscopic Technologies, and ~$9 million in Critical Care[10] 2024 Financial Guidance (Revised) - Revenue is projected to be between $1.305 billion and $1.315 billion, representing ~5% to ~6% growth in constant currency[17]